Background: There is increasing evidence that MTX-based chemotherapy is superior to HD-MTX alone. Rituximab (RTX) is effective in a variety of B-cell lymphomas and may enter the brain. The purpose of this study is to evaluate the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL). 
Introduction
Primary central nervous system lymphoma (PCNSL) is one of the most malignant intracranial tumors in adults and remains incurable. Until the 1990s, whole brain radiation therapy (WBRT) was considered the first treatment of choice for PCNSL because most PCNSLs show a marked response to radiation therapy (1) . However, the median overall survival (mOS) duration of these patients is only 12-17 months (1, 2) .
Chemotherapeutic agents have been used in treating systemic non-Hodgkin lymphoma, such as the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) regimen, which have produced notable responses; however, there is no evidence of a benefit from the CHOP regimen when used with radiation therapy (3) . Since the late 1980s, intravenous high-dose methotrexate (HD-MTX) has been known to have an effect against PCNSL. It is administered to the patients for over 2-4 h at a dose that leads to an intravascular osmotic gradient against the blood-brain barrier and achieves meaningful levels of the drug in the central nervous system (CNS). Chemotherapy regimens containing HD-MTX followed by WBRT have been shown to improve the mOS to over 40 months (4, 5) ; however, 10-35% of the patients are primarily refractory to these regimens and up to 60% of complete responders eventually relapse during follow-up (6, 7) .
There is now increasing evidence that MTX-based polychemotherapy is superior to HD-MTX alone. Rituximab (RTX), a humanized anti-CD20 monoclonal antibody, is effective in a variety of B-cell lymphomas and may enter the brain. Most PCNSLs are CD20+ and potentially responsive to RTX, which is currently frequently combined with HD-MTX alone or MTX-based polychemotherapy for patients with PCNSL in many institutions based on observations that the addition of RTX results in improved response rates (8) (9) (10) (11) . Recently, the international extranodal lymphoma study group (IELSG) reported that adding RTX to MTX-based polychemotherapy for PCNSL patients tended to improve progression-free survival and overall survival as well (12) . The present study reports the experience of a single institution as a retrospective case series of patients with recurrent PCNSL treated with RTX and HD-MTX.
Patients and methods

Study design and patients
This retrospective, observational study was approved by the National Cancer Center (NCC) Institutional Review Board. We reviewed our database of 49 immunocompetent patients with PCNSL treated at our institution between 2005 and 2012. Among these patients, we selected the relapsed patients with no limit on the number of previous relapses. All of these relapsed cases have had standard treatments that included biweekly HD-MTX (3.5-5.5 g/m 2 ) for 3-5 cycles followed by WBRT of 30-40 Gy with or without local boost therapy of 10 Gy. The inclusion criteria consisted of age ≥18; histological confirmation of diffuse large B-cell lymphoma (DLBCL) (all patients had pathology confirmed at the NCC); absence of systemic involvement of lymphoma both when the initial treatment was given and in the follow-up period leading up to the relapse; radiographical evidence of brain involvement at recurrence; and adequate bone marrow (absolute neutrophil count ≥1500/mm 3 , hemoglobin ≥8.0 g/dl, platelets ≥100 000/mm 3 ), renal function (creatinine clearance ≥50 ml/min) and hepatic function (sGOT/sGPT ≤ 3 times the upper limit of normal).
Treatment regimen
Patients with recurrent PCNSL, treated between 2005 and 2009, were administered 3-5 cycles of biweekly HD-MTX alone, the socalled 'rechallenge MTX.' This group of patients was utilized for historical data in this study and was named the MTX group. In this MTX group, HD-MTX (3.5-5.5 mg/m 2 ) was administered intravenously over 4 h with anti-emetic premedication and concurrent betamethasone. All patients received aggressive hydration prior to and after HD-MTX infusion to maintain a urine output of ≥100 ml/h and a urinary pH of >7, until serum MTX levels had decreased to ≤0.1 μM/l. Serum MTX levels were monitored on a regular basis. Leucovorin rescue was initiated 24 h after completion of MTX infusion and administered at 25 mg every 6 h until serum MTX levels were ≤0.1 μM/l.
From 2010 until 2012, patients with recurrence were assigned to receive 3-5 cycles of immunochemotherapy with combined biweekly RTX and HD-MTX. Intravenous RTX (375 mg/m 2 ) was given every 2 weeks. Chlorpheniramine (2 mg) and acetaminophen (400 mg) were given orally prior to RTX administration. Within 4 days after intravenous infusion of RTX, HD-MTX (3.5-5.5 mg/m 2 ) was administered intravenously. The administration of HD-MTX and the maintenance methods, which include anti-emetic medication, steroid use, hydration, leucovorin rescue and so on, were the same as for MTX only chemotherapy. These patients formed the RTX group.
Response criteria and evaluation
Baseline magnetic resonance imaging (MRI) was performed in all patients before initiating any therapeutic regimens. Tumor response was assessed by MRI performed after every cycle of the treatment and every 2 months after completion of the scheduled treatment.
Responses were determined utilizing the International Primary CNS Lymphoma Group (IPCG) response criteria (13) . Time to tumor progression (TTP) was defined as the time between the start of treatment and the day of radiographical progression or clinical deterioration, including death. Laboratory tests (complete blood counts, complete metabolic panel and calculated creatinine clearance) were performed at least every 2 days during the infusion of drugs and at every outpatient clinic visit, at least every 2 months after completing the treatment. A physical and neurological examination was performed every 2 weeks during the treatment and at every outpatient clinic visit thereafter. Toxicity and other clinical problems were assessed utilizing the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
Objectives and end points and analyses
The primary objective of this study was to determine the efficacy of an additional effect of RTX when added to HD-MTX in the treatment of recurrent PCNSL. The end points were median TTP and complete response (CR) rate. Statistical analysis was performed by use of z-test as appropriate. Kaplan-Meier survival distribution was estimated to assess median TTP, with assessment of differences by use of the log-rank test. P ≤ 0.05 was chosen to represent statistical significance. These analyses were performed to determine whether this RTX and HD-MTX regimen has an additional treatment effect on patients with recurrent PCNSL compared with the prespecified historical data from the NCC database, which included patients with recurrent PCNSL treated with HD-MTX alone between 2004 and 2009. All computations were carried out in JMP ® 7.0.1.
Results
Patient characteristics
A total of 23 patients with recurrent PCNSL were treated in our institution between January 2005 and December 2012. Nineteen of these patients were eligible for the study and 30 recurrences were analyzed in the study. Fifteen recurrences in 10 patients were treated with HD-MTX alone until December 2009 (MTX group) and 10 of these recurrences were a first relapse. The other 15 recurrences in 10 patients were treated with RTX and HD-MTX from January 2010 to December 2012 (RTX group) and nine of these recurrences were a first relapse. One patient received both treatment regimens because the patient was given MTX at the first and second relapse and was administered RTX and HD-MTX at the third relapse. The groups did not differ significantly in demographics at the recurrence (Table 1) .
Treatment course
Thirteen (86.6%) of the 15 recurrences of both groups completed all pre-planned chemotherapy cycles. Two (13.3%) of the 15 patients in both groups discontinued treatment prematurely. In the MTX group, two patients had progressive disease (PD) during first treatment course and were referred for palliative supportive care. In the RTX group, one patient experienced an infusion reaction at first administration and refused to receive further treatment containing RTX. Another patient had PD during second treatment course and was referred to palliative supportive care.
Response to chemotherapy and follow-up
In the MTX group, 10 (66.6%) of all 15 recurrences and 5 (56%) of the nine first ones to develop recurrence achieved a complete response (CR/CRu), 2 (13.3%) of 15 achieved a partial response (PR), and 3 (20%) of 15 had PD (Table 2 ). In the RTX group, the CR/CRu, PR, and PD rates of all 15 recurrences were the same as the MTX group but 6 (60%) of the 10 first relapses had a CR/CRu. There were apparently no statistical differences between the two groups.
Kaplan-Meier survival curves of the TTP in the MTX and RTX group were constructed. The median TTPs of all 15 recurrences and of the nine first ones were 9.1 months (range, 1.4-120.9 months) and 5.5 months (range, 1.4-40 months) in the MTX group, respectively. The median TTPs of all 15 recurrences and of the 10 first ones were 7.8 months (range, 0.9-52.3 months) and 7.8 months (range, 0.9-17.7 months) in the RTX group, respectively. We found no significant differences in the median TTP of all 15 recurrences (9.1 vs. 7.8 months, hazard ratio 1.02, 95% confidence interval 0.48-2.18, P = 0.94; Fig. 1a) or the median TTP of first relapses (5.5 vs. 7.8 months, hazard ratio 0.94, 95% confidence interval 0.35-2.49, P = 0.90; Fig. 1b) .
Toxicity
Overall, toxicity of chemotherapy was not significantly different between the groups (Table 3 ). An infusion reaction caused by RTX was seen in one patient. Both groups were associated with relatively high lymphopenia Grades 3 and 4. Hepatic toxicity Grade 3 or 4 was evident in two patients in both groups. There was no case of nephrotoxicity in either group. All treatment-related toxicities were manageable without severe events. Treatment did not have to be terminated prematurely because of toxicity except for the one infusion reaction in the RTX group. There was no treatment-associated death in either group.
Discussion
PCNSL has a poor survival duration of only a couple of months when treated with steroids, and only approximately a year after WBRT. Since the late 1980s, MTX has been known to have treatment efficacy against PCNSL, and MTX-based regimens have been used and modified (14, 15) ; however, there are limited survival benefits, with an OS duration of~40 months, and a 5-year survival rate of ≤10% (10,11,13). Furthermore, almost all patients eventually develop recurrences and die. For this reason, a second-line regimen is required in cases of relapse.
In the National Comprehensive Cancer Network guidelines MTX-rechallenge is proposed as a possible salvage therapy for patients who have experienced good response to prior MTX-based chemotherapies. In addition, when we analyze the summarized results of single-agent chemotherapy for patients with refractory or recurrent PCNSL, including those in our current study, in Table 4 (16-24), MTX-rechallenge seems to be the best treatment of choice for relapsed cases. However, the effects of administering MTXrechallenge alone have not been fully evaluated. Notably, these two improved outcomes listed in Table 4 do not solely reflect the usefulness of MTX-rechallenge because one study included patients who had received further consolidation therapy as an additional treatment modality while the other study excluded refractory cases during evaluation. Nevertheless, MTX is still a key drug for recurrent PCNSL even today. Most cases of PCNSL are known to be of the DLBCL type and are CD20+; thus, they are potentially expected to be responsive to RTX. While the interest in using RTX as therapy for PCNSL has grown, its efficacy against PCNSL is still controversial. Herein, we present the treatment effects of RTX plus MTX for salvage therapy. We also compared its efficacy with MTX monotherapy-rechallenge, using historical data, for comparison with patients who did not appear to have any cross-resistance to MTX. RTX has been used in patients with PCNSL and has been reported to be a promising drug. The first report of RTX for a patient with CNS disease was a case with a systemic lymphoma that developed cerebral spinal fluid (CSF) dissemination. In this case, after 4 weekly infusions of RTX (800 mg total dose per week) a marked neurological improvement as well as a clear reduction of leptomeningeal enhancement was documented.
Batchelor et al. reported monotherapy with RTX at a dose of 375 mg/m 2 as a single intravenous infusion every week for up to 8 weeks against 12 recurrent PCNSL. They showed occasional radiographic responses in up to 33% of patients and had a mPFS of 1.9 months and a mOS of 20.9 months. This report was the only study which evaluated the efficacy of RTX by itself for recurrent PCNSL. They concluded that these data provided evidence of the activity of intravenous RTX monotherapy (24) . Many studies have used RTX in combination with MTX-based chemotherapy, with or without irradiation, in patients with newly diagnosed PCNSL. Four studies reported the presence of additional efficacy of RTX in a non-randomized comparative study of MTXbased chemotherapy, with or without RTX (8, (25) (26) (27) . While three studies have shown that the addition of RTX to HD-MTX was associated with a better response and/or prognosis (8, 25, 26) , a study by Kansara et al. showed that RTX combined with HD-MTX did not appear to improve outcomes, possibly owing to its known trait of poor penetration of the CNS (27) . Favorable opinions for RTX seem to be dominant in literature, although there could have been an issue of publication bias.
Of the many studies that included MTX and RTX as treatment for newly diagnosed patients, four studies evaluated both MTX and RTX as combined chemotherapeutic agent (9, (26) (27) (28) . Of the four studies, two single-arm studies showed that the protocol composed of the HD-MTX and RTX regimen had a better efficacy than the HD-MTX-only regimen (9, 28) . In continuation with the discussion on comparative reports, two other studies that involved only two drugs, MTX and RTX, have also observed results similar to that mentioned above; one suggested a significant improvement in patient outcome (26) while the other reported no additional advantage (27) . Both studies warrant the need for prospective randomized trials with large sample sizes and longer follow-ups to ascertain better evidence (26, 27) .
For recurrent cases of PCNSL, few studies have reported the use of RTX in combination with other kinds of chemotherapeutic drugs. Mappa et al. (29) and Nayak et al. (30) have reported data on the feasibility and activity of RTX-containing chemotherapeutic regimens. One study consisted of RTX, ifosfamide and etoposide (29) , and the other included RTX and temozolomide (30) , with each protocol showing activity as a therapeutic option with manageable toxicity. Thus, reported evidence supports the use of RTX even in recurrent PCNSLs. However, no study focused solely on the use of RTX and MTX in relapsed cases. As most patients who achieve CR with MTX-based chemotherapy tend to eventually develop recurrence and because an additional effect of RTX can be anticipated, the evaluation for RTX in combination with MTX should be performed.
In this study we assessed the efficacy of the addition of RTX to HD-MTX monotherapy compared with historical data of HD-MTX monotherapyin patients with recurrent PCNSL who had previously responded to HD-MTX. We recognize that the biggest limitation of this retrospective study is that it provides results for only a limited number of patients. We believe that the reason for this was the inability to include enough patients, as this was a single-institutional study. However, we still deem these results worth reporting with special emphasis on our assessment of the use of two-drug regimen, containing RTX and MTX, in relapsed patients with PCNSL. In conclusion, the addition of RTX to HD-MTX monotherapy may not have a promising efficacy in the recurrent setting. However, there may be a possibility of response to RTX and HD-MTX polychemothrapy for some recurrent PCNSL patients who appear not to have any cross-resistance to MTX.
Conclusions
Based on this limited retrospective study, the addition of RTX to HD-MTX monotherapy may not be a promising strategy for recurrent PCNSL. A future study with a larger sample size, longer followup, or different RTX dosing/schedule is warranted.
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